Longstanding partners bring together
end-to-end workflows and leading CRISPR
Perturb-seq technologies setting a standard for single-cell studies
and enabling a 5
billion single-cell atlas ecosystem within three years
SAN
DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina,
Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing
and array-based technologies, today announced a collaboration with
Broad Clinical Labs to rapidly streamline and scale single-cell
projects with cutting-edge tools and workflows.
Together, the longstanding partners will set the standard for
scalable single-cell research and accelerate the development of a 5
billion cell atlas within the next three years.
"Disease doesn't wait, and neither do we – Broad Clinical Labs
and Illumina are unlocking the massive opportunities of single-cell
sequencing to build a deeper understanding of biology," said
Steve Barnard, Chief Technology
Officer at Illumina. "Illumina has set the standard in whole genome
sequencing, and now, with Broad's deep experience and long history
of translating complex molecular biology assays into
high-throughput, high quality workflows, we're doing the same with
single-cell technology to advance precision health."
"Supporting the entire -omics ecosystem in building these
capabilities enables significantly greater insights into key
drivers of disease and more rapid translation of these insights
into better precision care," said Niall
Lennon, Chairman of the Board and Chief Scientific Officer
at Broad Clinical Labs.
"By expanding our partnership to single-cell solutions, we're
making significant strides to understand the roots of disease and
close the gap between new biological insights and impact for
patients," said Aziz Al'Khafaji, Director of Molecular R&D at
Broad Clinical Labs. "The capabilities we're building, like
combining Perturb-seq with Illumina Single Cell 3' RNA Prep, will
support rapid and consistent data generation like we've
demonstrated in the whole genome space, giving the research
community the ability to create billion-cell atlas studies to make
the next discoveries."
The combination of Illumina's Single Cell Prep, NovaSeq™ X
Plus platform, 25B flow cell and DRAGEN™ analysis
software creates a seamless end-to-end workflow enabling the
high-throughput processing of single-cell samples.
Broad Clinical Labs will use this leading workflow alongside
state-of-the-art techniques like Perturb-seq, CRISPR screens, and
other cutting-edge applications. Together, these capabilities will
help researchers process and analyze unprecedented volumes of
single-cell reads with unparalleled speed and accuracy to make
large-scale functional genomics studies possible and accelerate
discovery in areas such as disease modeling and drug
development.
Use of forward-looking statements
This release may contain forward-looking statements that involve
risks and uncertainties. Among the important factors to which our
business is subject that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing and launching new products and
services, including modifying and scaling manufacturing operations,
and reliance on third-party suppliers for critical components; (ii)
our ability to manufacture robust instrumentation and consumables;
and (iii) the acceptance by customers of our newly launched
products, which may or may not meet our and their expectations,
together with other factors detailed in our filings with the
Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to
update these forward-looking statements, to review or confirm
analysts' expectations, or to provide interim reports or updates on
the progress of the current quarter.
About Broad Clinical Labs
Broad Clinical Laboratories was founded in 2013 as a non-profit
subsidiary of Broad Institute of MIT
and Harvard to accelerate the world
toward a better understanding, diagnosis, and treatment of disease
by pursuing projects, developing products, and driving adoption of
cutting edge -omics technologies and novel molecular assays. Broad
Clinical Labs is a leader in translational genomics, having
sequenced over 700,000 genomes in service of its mission to
accelerate the understanding and diagnosis of human disease.
www.broadclinicallabs.org
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X,
Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli
Schwartz
858-291-6421
IR@illumina.com
Media:
Christine
Douglass
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-and-broad-clinical-labs-usher-in-new-era-of-drug-discovery-with-collaboration-to-rapidly-scale-single-cell-solutions-302382129.html
SOURCE Illumina, Inc.
